(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2007 (11.10.2007)

PCT

(10) International Publication Number
WO 2007/113222 A3

(51) International Patent Classification:
A61K 39/085 (2006.01) *A61P 31/04* (2006.01)
A61K 31/70 (2006.01)

(21) International Application Number:
PCT/EP2007/053057

(22) International Filing Date: 29 March 2007 (29.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0606416.6	30 March 2006 (30.03.2006)	GB
60/787,249	30 March 2006 (30.03.2006)	US
60/787,587	30 March 2006 (30.03.2006)	US

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut, 89, B-1330 Rixensart (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **DENOEL, Philippe** [BE/BE]; GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart (BE). **POOLMAN, Jan** [NL/BE]; GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agents: **JOHNSTON, Caroline, Louise** et al.; Glaxo-SmithKline, Corporate Intellectual Property, (CN925.1), Brentford, Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
29 November 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMMUNOGENIC COMPOSITION

(57) Abstract: The present application relates to immunogenic compositions comprising Type 5 and/or 8 capular polysaccharide or oligosaccharide from *S. aureus* having between 30-100% O- acetylation. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising Type 5 and/or 8 capsular polysaccharides with 30-100% O- acetylation are also described.

WO 2007/113222 A3